FibroBiologics (FBLG) Company Overview

Profile

Full Name:

FibroBiologics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 1, 2024

Indexes:

Not included

Description:

FibroBiologics focuses on developing innovative therapies using fibroblast cells for regenerative medicine. The company aims to harness the potential of these cells to treat various conditions, including chronic pain and tissue damage, promoting healing and improving patients' quality of life.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 27, 24 D. Boral Capital
Buy
Dec 12, 24 Rodman & Renshaw
Buy
Nov 20, 24 D. Boral Capital
Buy
Nov 13, 24 HC Wainwright & Co.
Buy
Nov 13, 24 D. Boral Capital
Buy
Oct 30, 24 HC Wainwright & Co.
Buy
Oct 18, 24 EF Hutton
Buy
Sep 24, 24 Maxim Group
Buy
Sep 13, 24 EF Hutton
Buy
Sep 4, 24 EF Hutton
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FBLG
globenewswire.comFebruary 5, 2025

HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET. The event will feature presentations from the following members of the Company's management: Pete O'Heeron, Chief Executive Officer Hamid Khoja, PhD, Chief Scientific Officer Robert Hoffman, Interim Chief Financial Officer The event will highlight FibroBiologics' research and development strategy for advancing fibroblast-based therapeutics to address chronic diseases.

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
FBLG
globenewswire.comDecember 30, 2024

HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has closed the second $5 million tranche of the previously announced Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD. (“Yorkville”), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.

D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
FBLG
globenewswire.comDecember 30, 2024

HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN LTD. (“Yorkville”), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.

FibroBiologics Announces $25 Million Financing
FibroBiologics Announces $25 Million Financing
FibroBiologics Announces $25 Million Financing
FBLG
globenewswire.comDecember 23, 2024

HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN LTD. (“Yorkville”), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
FBLG
globenewswire.comNovember 19, 2024

HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based therapeutic approach.

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
FBLG
globenewswire.comNovember 14, 2024

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts or other Tissue Factor (TF)-expressing cells to prevent IBMIR-mediated blood clotting.

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
FBLG
globenewswire.comOctober 29, 2024

HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced promising new findings from its artificial thymus organoid program. Recent results from the artificial thymus organoid program showed that fibroblasts and thymus-derived cell organoids can persist and function for over 50 days post-transplantation, with vascularization and the generation of a diverse array of mature T cells in animal models.

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
FBLG
globenewswire.comOctober 18, 2024

HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development, testing, and manufacturing solutions provider established a master services agreement to develop and manufacture FibroBiologics' therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for utilization in a diabetic foot ulcer (DFU) clinical trial slated to begin in 2025.

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
FBLG
globenewswire.comOctober 16, 2024

HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of a patent from the European Patent Office (Patent Number 19795975.2) covering methods and compositions for the treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual.

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
FBLG
globenewswire.comOctober 11, 2024

HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Pete O'Heeron, Chief Executive Officer of FibroBiologics, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 10:00 a.m. ET.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for FibroBiologics?
  • Does FibroBiologics pay dividends?
  • What sector is FibroBiologics in?
  • What industry is FibroBiologics in?
  • What country is FibroBiologics based in?
  • When did FibroBiologics go public?
  • Is FibroBiologics in the S&P 500?
  • Is FibroBiologics in the NASDAQ 100?
  • Is FibroBiologics in the Dow Jones?
  • When was FibroBiologics's last earnings report?
  • When does FibroBiologics report earnings?
  • Should I buy FibroBiologics stock now?

What is the ticker symbol for FibroBiologics?

The ticker symbol for FibroBiologics is NASDAQ:FBLG

Does FibroBiologics pay dividends?

No, FibroBiologics does not pay dividends

What sector is FibroBiologics in?

FibroBiologics is in the Healthcare sector

What industry is FibroBiologics in?

FibroBiologics is in the Biotechnology industry

What country is FibroBiologics based in?

FibroBiologics is headquartered in United States

When did FibroBiologics go public?

FibroBiologics's initial public offering (IPO) was on February 1, 2024

Is FibroBiologics in the S&P 500?

No, FibroBiologics is not included in the S&P 500 index

Is FibroBiologics in the NASDAQ 100?

No, FibroBiologics is not included in the NASDAQ 100 index

Is FibroBiologics in the Dow Jones?

No, FibroBiologics is not included in the Dow Jones index

When was FibroBiologics's last earnings report?

FibroBiologics's most recent earnings report was on Nov 12, 2024

When does FibroBiologics report earnings?

The next expected earnings date for FibroBiologics is Feb 28, 2025

Should I buy FibroBiologics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions